Pharmaceuticals

Global Trastuzumab Biosimilars Market 2026 surging to $24.48 billion by 2030

March 25, 2026March 25, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Trastuzumab Biosimilars Market At The End Of The 2026–2030 Forecast Period?

The trastuzumab biosimilars market size has experienced significant expansion recently. Its valuation is projected to increase from $6.9 billion in 2025 to reach $8.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 28.5%. This historical expansion can be linked to several factors including the elevated occurrence of HER2 positive breast cancer, the expiration of trastuzumab patent exclusivity, an increase in oncology drug expenses, established regulatory pathways for biosimilars, and the growing acceptance within hospital oncology departments.

The trastuzumab biosimilars market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $24.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 28.9%. This forecasted growth stems from several factors, including the rising incidence of cancer, the extension of indications to include gastric cancer, supportive reimbursement policies for biosimilars, enhanced trust among physicians, and increased initiatives aimed at curbing healthcare costs. Key developments anticipated during this period encompass the swift adoption of oncology biosimilars, enhanced availability of HER2 targeted treatments, intense price rivalry within breast cancer therapy, broader application in hospital oncology settings, and increasing willingness to switch to biosimilars.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

What Primary Drivers Are Shaping The Development Of The Trastuzumab Biosimilars Market?

The increasing occurrence of breast and gastric cancer has fueled the expansion of the trastuzumab biosimilars market. Trastuzumab biosimilar serves as a treatment for human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For instance, in September 2023, the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, reported that approximately 297,790 new cases of invasive breast cancer were anticipated to be diagnosed in women in 2023, with about 43,700 women expected to succumb to breast cancer in the same year. Additionally, Cancer India indicates that breast cancer is the most common cancer in women in India, constituting 14% of all female cancers. Consequently, the growing incidence of breast and gastric cancer boosts the demand for trastuzumab biosimilar, which offers a cost-effective alternative to expensive medicines, thereby propelling the trastuzumab biosimilars market.

What Segment Types Make Up The Trastuzumab Biosimilars Market?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Which Market Trends Are Creating New Opportunities In The Trastuzumab Biosimilars Market?

Leading industry participants are consistently focusing on introducing new products into unaddressed regions, a trend that is significantly shaping the market for trastuzumab biosimilars. Companies operating within the trastuzumab biosimilars market are undertaking various strategic endeavors, such as developing new products, forming partnerships, and expanding their geographical reach and product portfolios, all to maintain their competitive standing and better cater to customer requirements. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer. HERCESSI is prescribed for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. While generally aggressive, HER2-positive cancers typically respond effectively to targeted therapies. HERCESSI operates by binding to the HER2 receptor, thereby inhibiting its activity and slowing down the replication of cancer cells.

Who Are The Key Players Driving Competition In The Trastuzumab Biosimilars Market?

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

Read the full trastuzumab biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

How Does The Trastuzumab Biosimilars Market Perform Across Major Global Regions?

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Trastuzumab Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3400&type=smp

Browse Through More Reports Similar to the Global Trastuzumab Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795